Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab (GLS-010) in recurrent or metastatic cervical cancer
NCT03972722Phase 2Unknown
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab in Cervical Cancer (CC), sponsored by Guangzhou Gloria Biosciences Co., Ltd.. Status: unknown.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03972722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972722.